Zevra Therapeutics, Inc. Proceeds from Issuance of Debt
Zevra Therapeutics, Inc. (ZVRA) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-03-09
- Zevra Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2024-06-30 was $58.99M.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for fiscal 2024 was $58.99M, a 39.03% increase from fiscal 2023.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for fiscal 2023 was $42.43M, a 231.49% increase from fiscal 2022.
- Zevra Therapeutics, Inc. proceeds from issuance of debt for fiscal 2022 was $12.80M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $58.99M derived: sum of 3 quarters · filed 2026-03-09 | $58.99M 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $58.99M derived: sum of 2 quarters · filed 2024-11-13 | $58.99M 10-Q · filed 2024-11-13 | $62.62M derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-06-30 | $58.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $58.99M 10-Q · filed 2024-08-14 | $62.62M derived: sum of 3 quarters · filed 2025-03-12 | $88.62M derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $3.63M derived: sum of 2 quarters · filed 2025-03-12 | $29.63M derived: sum of 3 quarters · filed 2025-03-12 | $29.52M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $29.63M derived: sum of 2 quarters · filed 2025-03-12 | $29.52M derived: sum of 3 quarters · filed 2025-03-12 | $42.43M 10-K · filed 2025-03-12 |
| 2023-09-30 | $26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $25.89M derived: sum of 2 quarters · filed 2024-11-13 | $38.80M 10-Q · filed 2024-11-13 | $38.80M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $12.80M 10-Q · filed 2024-08-14 | $12.80M derived: sum of 3 quarters · filed 2024-08-14 | $12.80M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $12.91M 10-Q · filed 2024-05-09 | $12.91M derived: sum of 2 quarters · filed 2024-05-09 | $12.91M derived: sum of 3 quarters · filed 2024-05-09 | $25.71M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $12.80M derived: sum of 3 quarters · filed 2024-04-01 | $12.80M 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $12.80M derived: sum of 2 quarters · filed 2023-11-07 | $12.80M 10-Q · filed 2023-11-07 | $12.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $12.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $12.80M 10-Q · filed 2023-08-14 | $12.80M derived: sum of 3 quarters · filed 2023-08-14 | $12.80M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $0.00 derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $0.00 derived: sum of 2 quarters · filed 2018-03-30 | $0.00 derived: sum of 3 quarters · filed 2018-03-30 | $82.80M 10-K · filed 2018-03-30 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $82.80M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $82.80M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $82.80M 10-Q · filed 2017-05-22 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $0.00 derived: sum of 2 quarters · filed 2017-03-10 | $25.00M 10-K · filed 2017-03-10 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $25.00M 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $25.00M 10-Q · filed 2015-08-14 | |||
| 2013-12-31 | $3.85M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |